[Piribedil in the treatment of Parkinson disease (author's transl)].
Seventeen patients with either Parkinson's disease or post-encephalitic parkinsonism were treated with Piribedil, an apomorphine-like drug, in single blind conditions for a period ranging from five weeks to twenty-four months. The analysis of the results shows that Piribedil modifies the extrapiramidal symptomatology being specially effective against the tremor either when used alone or in association with L-Dopa. The side effects noticed during treatment with Piribedil are similar to those of Apomorphine, and are dose-dependent.
D000368:Aged; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004357:Drug Synergism; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000188:drug therapy; D009127:Muscle Rigidity / Q000188:drug therapy; D010300:Parkinson Disease / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use*; D010891:Piribedil / Q000008:administration & dosage / Q000627:therapeutic use*; D014202:Tremor / Q000188:drug therapy
D010879:Piperazines; D007980:Levodopa; D010891:Piribedil
Ruolo del piribedil nel trattamento del morbo di Parkinson